DK1663236T3 - Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanat - Google Patents
Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanatInfo
- Publication number
- DK1663236T3 DK1663236T3 DK04768282T DK04768282T DK1663236T3 DK 1663236 T3 DK1663236 T3 DK 1663236T3 DK 04768282 T DK04768282 T DK 04768282T DK 04768282 T DK04768282 T DK 04768282T DK 1663236 T3 DK1663236 T3 DK 1663236T3
- Authority
- DK
- Denmark
- Prior art keywords
- methylpyrazin
- bisphosphonate
- oxadiazol
- sulfonamide
- pyridine
- Prior art date
Links
- 229940122361 Bisphosphonate Drugs 0.000 title 1
- FJHHZXWJVIEFGJ-UHFFFAOYSA-N N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide Chemical compound COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=2OC=NN=2)C=C1 FJHHZXWJVIEFGJ-UHFFFAOYSA-N 0.000 title 1
- 150000004663 bisphosphonates Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0320806.3A GB0320806D0 (en) | 2003-09-05 | 2003-09-05 | Therapeutic treatment |
| PCT/GB2004/003733 WO2005023264A1 (en) | 2003-09-05 | 2004-09-02 | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1663236T3 true DK1663236T3 (da) | 2009-05-25 |
Family
ID=29226541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04768282T DK1663236T3 (da) | 2003-09-05 | 2004-09-02 | Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanat |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20060287241A1 (de) |
| EP (2) | EP1663236B1 (de) |
| JP (1) | JP2007504265A (de) |
| KR (1) | KR20060069857A (de) |
| CN (1) | CN1878555A (de) |
| AR (1) | AR045572A1 (de) |
| AT (1) | ATE424206T1 (de) |
| AU (1) | AU2004269956B2 (de) |
| BR (1) | BRPI0413974A (de) |
| CA (1) | CA2537096A1 (de) |
| CO (1) | CO5650255A2 (de) |
| CY (1) | CY1110315T1 (de) |
| DE (1) | DE602004019795D1 (de) |
| DK (1) | DK1663236T3 (de) |
| ES (1) | ES2321620T3 (de) |
| GB (1) | GB0320806D0 (de) |
| HK (1) | HK1090294A1 (de) |
| HR (1) | HRP20090229T1 (de) |
| IL (1) | IL173817A (de) |
| IS (1) | IS8365A (de) |
| MX (1) | MXPA06002485A (de) |
| NO (1) | NO20061051L (de) |
| NZ (1) | NZ545468A (de) |
| PL (1) | PL1663236T3 (de) |
| PT (1) | PT1663236E (de) |
| RU (1) | RU2398588C2 (de) |
| SI (1) | SI1663236T1 (de) |
| TW (1) | TW200509934A (de) |
| WO (1) | WO2005023264A1 (de) |
| ZA (1) | ZA200601871B (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| PL2209501T3 (pl) | 2007-10-12 | 2012-03-30 | Astrazeneca Ab | Kompozycja zibotentanu zawierająca mannitol i celulozę mikrokrystaliczną |
| PT2252627T (pt) | 2008-01-24 | 2017-07-24 | Esperance Pharmaceuticals | Constructos de fusão de domínio lítico e métodos para produzir e utilizar os mesmos |
| KR102460297B1 (ko) | 2012-10-30 | 2022-10-28 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 항체/약물 컨쥬게이트 및 이의 사용 방법 |
| US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
| US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
| US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9849160B2 (en) * | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
| US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) * | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| US4234571A (en) | 1979-06-11 | 1980-11-18 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone |
| US4431635A (en) | 1979-06-13 | 1984-02-14 | Coy David Howard | LH-RH Antagonists |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4547370A (en) | 1983-11-29 | 1985-10-15 | The Salk Institute For Biological Studies | GnRH Antagonists |
| US5003011A (en) | 1985-04-09 | 1991-03-26 | The Administrators Of The Tulane Educational Fund | Therapeutic decapeptides |
| US4801577A (en) | 1987-02-05 | 1989-01-31 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists |
| US4851385A (en) | 1987-07-15 | 1989-07-25 | Indiana University Foundation | LHRH antagonist analogs having low histamine-release activity |
| US4935491A (en) | 1987-08-24 | 1990-06-19 | Board Of Regents, The University Of Texas System | Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine |
| US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5300492A (en) | 1988-02-10 | 1994-04-05 | Tap Pharmaceuticals | LHRH analogs |
| US4992421A (en) | 1988-04-19 | 1991-02-12 | Abbott Laboratories | Luteinizing hormone releasing hormone antagonist |
| US5296468A (en) | 1989-10-30 | 1994-03-22 | The Salk Institute For Biological Studies | GnRH analogs |
| US5668254A (en) | 1990-05-11 | 1997-09-16 | Romano Deghenghi | D-2-alkyl-tryptophan and peptides containing same |
| US5171635A (en) | 1990-10-10 | 1992-12-15 | E. I. Du Pont De Nemours And Company | Composite wire construction |
| US5371070A (en) | 1992-11-09 | 1994-12-06 | The Salk Institute For Biological Studies | Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins |
| US5413990A (en) | 1993-08-06 | 1995-05-09 | Tap Pharmaceuticals Inc. | N-terminus modified analogs of LHRH |
| US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
| UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| WO1997014697A1 (en) | 1995-10-19 | 1997-04-24 | Takeda Chemical Industries, Ltd. | Thienopyridine derivatives as gonadotropin releasing hormone antagonists |
| US5780435A (en) * | 1995-12-15 | 1998-07-14 | Praecis Pharmaceuticals Incorporated | Methods for treating prostate cancer with LHRH-R antagonists |
| DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
| US20020055457A1 (en) * | 2000-08-07 | 2002-05-09 | Janus Todd J. | Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| SE0100566D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| SE0100567D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| US20030092757A1 (en) * | 2001-04-11 | 2003-05-15 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| MXPA03010007A (es) * | 2001-05-02 | 2004-02-12 | Novartis Ag | USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA. |
| SE0101692D0 (sv) | 2001-05-14 | 2001-05-14 | Astrazeneca Ab | Compounds |
| US20050215528A1 (en) * | 2001-08-10 | 2005-09-29 | Shuichi Furuya | Gnrh agonist combination drugs |
| US7098305B2 (en) | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| DE10155076A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
| GB0223367D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Therapeutic treatment |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
-
2003
- 2003-09-05 GB GBGB0320806.3A patent/GB0320806D0/en not_active Ceased
-
2004
- 2004-09-01 TW TW093126404A patent/TW200509934A/zh unknown
- 2004-09-02 CA CA002537096A patent/CA2537096A1/en not_active Abandoned
- 2004-09-02 EP EP04768282A patent/EP1663236B1/de not_active Expired - Lifetime
- 2004-09-02 RU RU2006110736/15A patent/RU2398588C2/ru not_active IP Right Cessation
- 2004-09-02 EP EP08166467A patent/EP2018865A3/de not_active Withdrawn
- 2004-09-02 NZ NZ545468A patent/NZ545468A/en unknown
- 2004-09-02 PT PT04768282T patent/PT1663236E/pt unknown
- 2004-09-02 DK DK04768282T patent/DK1663236T3/da active
- 2004-09-02 PL PL04768282T patent/PL1663236T3/pl unknown
- 2004-09-02 CN CNA2004800329117A patent/CN1878555A/zh active Pending
- 2004-09-02 US US10/569,583 patent/US20060287241A1/en not_active Abandoned
- 2004-09-02 AU AU2004269956A patent/AU2004269956B2/en not_active Ceased
- 2004-09-02 JP JP2006525875A patent/JP2007504265A/ja active Pending
- 2004-09-02 MX MXPA06002485A patent/MXPA06002485A/es active IP Right Grant
- 2004-09-02 DE DE602004019795T patent/DE602004019795D1/de not_active Expired - Lifetime
- 2004-09-02 WO PCT/GB2004/003733 patent/WO2005023264A1/en active Application Filing
- 2004-09-02 AT AT04768282T patent/ATE424206T1/de active
- 2004-09-02 SI SI200431103T patent/SI1663236T1/sl unknown
- 2004-09-02 BR BRPI0413974-7A patent/BRPI0413974A/pt not_active IP Right Cessation
- 2004-09-02 ES ES04768282T patent/ES2321620T3/es not_active Expired - Lifetime
- 2004-09-02 KR KR1020067004331A patent/KR20060069857A/ko not_active Application Discontinuation
- 2004-09-03 AR ARP040103164A patent/AR045572A1/es unknown
-
2006
- 2006-02-20 IL IL173817A patent/IL173817A/en not_active IP Right Cessation
- 2006-03-01 CO CO06020457A patent/CO5650255A2/es not_active Application Discontinuation
- 2006-03-03 NO NO20061051A patent/NO20061051L/no not_active Application Discontinuation
- 2006-03-03 ZA ZA200601871A patent/ZA200601871B/xx unknown
- 2006-03-20 IS IS8365A patent/IS8365A/is unknown
- 2006-10-06 HK HK06111051.7A patent/HK1090294A1/xx not_active IP Right Cessation
-
2009
- 2009-04-20 HR HR20090229T patent/HRP20090229T1/xx unknown
- 2009-05-05 CY CY20091100480T patent/CY1110315T1/el unknown
- 2009-05-11 US US12/463,607 patent/US20100004181A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1663236T3 (da) | Kombination, der omfatter n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]-phenyl)-pyridin-3-sulfonamid og et bihosphanat | |
| NO2017051I1 (no) | Kariprazin, eventuelt i form av et salt, inkludert kariprazin hydroklorid | |
| DE60317797D1 (de) | Strahlungshärtbare prepolymere | |
| PT1482798E (pt) | Misturas fungicidas a base de protioconazol e de trifloxystrobina | |
| ATE308544T1 (de) | N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren | |
| DE502004002833D1 (de) | Alkoxysilanterminierte prepolymere | |
| DK1467789T3 (da) | Lægemiddeldispenser | |
| ATE363463T1 (de) | 2-(2,6-dichlorphenyl)-diarylimidazole | |
| DE50303339D1 (de) | Zielgerät für einen Verriegelungsnagel | |
| ATE304015T1 (de) | Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren | |
| DE50301281D1 (de) | Zielgerät für einen Verriegelungsnagel | |
| IS2704B (is) | Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini | |
| DE602004013723D1 (de) | Hundeimpfstoffe gegen bordetella bronchiseptica | |
| EE200400075A (et) | Peroraalsed antidiabeetilised ained | |
| DE60318991D1 (de) | Verteilter fehlerbeständiger gemeinsam benutzter speicher | |
| FR2838302B1 (fr) | Maillot debain a zones elastiques | |
| FI20031014A (fi) | Siirtolaite | |
| DK1443821T3 (da) | Svampedræbende sammensætning baseret på et pyridylmethylbenzamid- og et valinamid-derivat | |
| ITRM20020504A1 (it) | Compattatore essiccatore a gabbia a doppio flusso e | |
| ATE489359T1 (de) | Amidoacetonitril-verbindungen gegen parasiten | |
| PT1475060E (pt) | Juncao articulada para uma cinta pos-operatoria | |
| IL182854A0 (en) | A combination of n - (3 - methoxy - 5 - methylpyrazin - 2 - yl) - 2 - (4 - [1,3,4 - oxadiazol - 2 - yl] phenyl) pyridine - 3 - sulphonamide and an anti - mitotic agent for the treatment of cancer | |
| FR2892125B1 (fr) | Composition a base d'hydrofluorocarbures | |
| DK1656021T3 (da) | Lagerstabile herbicide blandinger med metazachlor | |
| IS7581A (is) | Lyfjasamsetning |